Profile data is unavailable for this security.
About the company
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.
- Revenue in USD (TTM)112.98m
- Net income in USD-8.50m
- Incorporated1989
- Employees296.00
- LocationNatural Alternatives International Inc1535 Faraday AvenueCARLSBAD 92008United StatesUSA
- Phone+1 (760) 736-7700
- Fax+1 (760) 744-9589
- Websitehttps://www.nai-online.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cara Therapeutics Inc | 8.69m | -95.53m | 17.01m | 55.00 | -- | 24.05 | -- | 1.96 | -1.75 | -1.75 | 0.1589 | 0.0129 | 0.1042 | 0.6312 | 4.59 | 157,927.30 | -114.63 | -35.76 | -142.84 | -40.82 | 56.44 | -- | -1,099.76 | -162.10 | 4.71 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Marinus Pharmaceuticals Inc | 31.47m | -140.49m | 17.75m | 165.00 | -- | -- | -- | 0.5642 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 19.54m | 1.00 | -- | -- | -- | 195,396.80 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cyclo Therapeutics Inc | 870.72k | -24.80m | 20.06m | 8.00 | -- | -- | -- | 23.04 | -0.9232 | -0.9232 | 0.0322 | -0.4683 | 0.1605 | 0.342 | 3.54 | 108,840.00 | -457.10 | -132.22 | -- | -215.17 | 91.24 | 90.37 | -2,848.18 | -1,114.04 | 0.1614 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Nexgel Inc | 6.73m | -3.53m | 22.13m | 19.00 | -- | 4.74 | -- | 3.29 | -0.5815 | -0.5815 | 1.10 | 0.6902 | 0.6558 | 3.21 | 6.56 | 354,105.30 | -37.28 | -44.61 | -51.10 | -56.19 | 31.61 | 5.02 | -56.85 | -180.98 | 0.9291 | -- | 0.2235 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| BioXcel Therapeutics Inc | 2.28m | -71.00m | 23.25m | 74.00 | -- | -- | -- | 10.21 | -2.15 | -2.15 | 0.0637 | -2.02 | 0.0305 | 1.14 | 6.17 | 30,756.76 | -95.08 | -74.57 | -168.28 | -84.06 | 10.98 | -- | -3,119.33 | -32,300.74 | 1.81 | -6.54 | 5.55 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -26.86m | 23.34m | 59.00 | -- | 10.81 | -- | -- | -7.48 | -7.48 | 0.00 | 0.3172 | 0.00 | -- | -- | 0.00 | -132.55 | -76.92 | -222.42 | -89.61 | -- | -- | -- | -- | -- | -25.48 | 0.7813 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Natural Alternatives International, Inc. | 112.98m | -8.50m | 26.34m | 296.00 | -- | 0.3286 | -- | 0.2332 | -1.45 | -1.45 | 19.19 | 12.94 | 0.7028 | 4.35 | 8.25 | 381,679.10 | -5.29 | 2.33 | -6.04 | 2.80 | 5.30 | 14.24 | -7.53 | 2.06 | 1.50 | -9.35 | 0.1536 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| Dare Bioscience Inc | 1.88m | -3.60m | 28.08m | 23.00 | -- | -- | -- | 14.93 | -0.5276 | -0.5276 | 0.2303 | -0.1737 | 0.0873 | -- | 2.28 | 81,796.52 | -16.72 | -109.51 | -199.47 | -246.26 | 3.50 | -- | -191.61 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| KALA BIO Inc | 0.00 | -38.96m | 30.18m | 43.00 | -- | 4.40 | -- | -- | -12.47 | -12.47 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -67.64 | -57.83 | -96.17 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.21 | 0.8367 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 30.70m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Opus Genetics Inc | 8.38m | -27.19m | 30.94m | 14.00 | -- | 0.7517 | -- | 3.69 | -1.09 | -1.09 | 0.3369 | 1.31 | 0.1772 | -- | 1.14 | 598,642.90 | -57.50 | -58.31 | -64.30 | -65.94 | -- | -- | -324.45 | -137.92 | -- | -- | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| ImmuCell Corp | 23.84m | -3.81m | 32.62m | 74.00 | -- | 1.22 | -- | 1.37 | -0.4856 | -0.4856 | 3.03 | 2.99 | 0.5357 | 2.35 | 11.43 | 301,746.80 | -8.56 | -5.16 | -9.39 | -5.53 | 26.71 | 40.04 | -15.99 | -12.64 | 1.44 | -6.21 | 0.2922 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Incannex Healthcare Inc | 86.00k | -23.15m | 34.76m | 9.00 | -- | 5.27 | -- | 404.14 | -1.40 | -1.40 | 0.0052 | 0.3738 | -- | -- | -- | 9,555.56 | -- | -130.12 | -- | -148.24 | -- | -- | -26,922.09 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
Data as of Nov 21 2024. Currency figures normalised to Natural Alternatives International Inc's reporting currency: US Dollar USD
29.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 415.76k | 6.71% |
| Caldwell Sutter Capital, Inc. (Investment Management)as of 30 Sep 2024 | 414.48k | 6.69% |
| Renaissance Technologies LLCas of 16 Oct 2024 | 338.06k | 5.45% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 240.24k | 3.88% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 170.09k | 2.74% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 126.06k | 2.03% |
| Geode Capital Management LLCas of 30 Sep 2024 | 45.06k | 0.73% |
| Empowered Funds LLCas of 30 Sep 2024 | 24.05k | 0.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 18.33k | 0.30% |
| Cutter & Co. Brokerage, Inc. (Investment Management)as of 30 Sep 2024 | 16.71k | 0.27% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
